CIAM
XFOR icon

Caitong International Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Caitong International Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Buy
+30
New +$123 ﹤0.01% 2089

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caitong International Asset Management's XFOR Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 30 shares worth $140. The stake represents ﹤0.01% of the portfolio and ranks #2089 among its holdings.

89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Caitong International Asset Management held 30 shares of X4 Pharmaceuticals worth $140 as of Q2 2026.
  • X4 Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2089 holding.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.